Core Viewpoint - *ST Sailong has experienced a complete resignation of its board members, indicating a significant change in corporate governance and potential implications for the company's future direction [1][3][4]. Board Resignation - All nine members of the fourth board of directors of *ST Sailong have submitted their resignation reports, including key figures such as Chairman Cai Nanguai and other executives [3][4]. - Cai Nanguai will continue to hold other positions within the company despite resigning as Chairman and CEO, and he holds 67.51 million shares, representing 47.23% of the company’s controlling shareholder [3][4]. - The resignations will lead to a board composition below the minimum required by the company's articles of association, necessitating the continuation of their roles until new directors are elected [4]. New Board Candidates - The board has proposed new candidates for the fourth board of directors, including non-independent and independent directors, to be elected at the upcoming shareholders' meeting [4][5]. Management Changes - The board has approved the appointment of Chen Ke as the new CEO, effective immediately following the board meeting [5]. - Chen Ke has a background in accounting and has held various positions in investment and asset management [6]. Financial Performance - *ST Sailong has projected a net loss of between 13 million and 18 million yuan for the first half of the year, a significant decline from a profit of 1.76 million yuan in the same period last year [7]. - The expected loss translates to a basic earnings per share loss of between 0.0739 yuan and 0.1023 yuan, compared to a profit of 0.0100 yuan per share in the previous year [7]. Stock Market Activity - On August 8, *ST Sailong's stock price reached a limit-up, closing at 16.81 yuan per share, with a total market capitalization of 2.959 billion yuan [7][8].

8月10日晚间，*ST赛隆公告称，因公司控制权已发生变更，公司第四届董事会所有成员和部分高管均递交了辞职报告。 同时，海南雅亿共赢科技合伙企业（有限合伙）（以下简称海南雅亿）作为*ST赛隆的新任控股股东，提名贾晋斌等9人为*ST赛隆第四届董事会的董事候 选人。 8月8日尾盘，*ST赛隆突然涨停。截至当日收盘，*ST赛隆股价报16.81元/股，涨幅达5%，总市值为29.59亿元。 董事会所有成员辞职 *ST赛隆公告称，近日，公司收到董事长兼总裁蔡南桂、董事唐霖、董事兼常务副总裁刘达文、董事兼副总裁李剑峰、董事邓拥军、独立董事潘传云、独 立董事陈小辛、独立董事李公奋，以及董事、副总裁、董事会秘书张旭等9人递交的辞职报告。 *ST赛隆将迎新一任管理层 *ST赛隆公告称，蔡南桂等人申请辞去公司董事等职务，主要是公司控制权已经发生变更。 7月9日，*ST赛隆收到蔡南桂、唐霖与海南雅亿的通知，获悉蔡南桂、唐霖向海南雅亿协议转让所持*ST赛隆14.16%股份的过户登记手续已经办理完成， 并且取得中国证券登记结算有限责任公司出具的《证券过户登记确认书》。 目前，*ST赛隆第四届董事会共有9名董事。这意味着，*ST赛隆第四届董 ...

Group 1 - The company *ST Sailong (002898.SZ) announced a change in control, leading to the resignation of several key executives including the chairman and president Cai Nanguai, and other board members [1] - The resigning board members will continue to fulfill their duties until new directors are elected at the shareholders' meeting [1] - The company will expedite the process of board member replacement in accordance with relevant regulations [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永安國際有限公司 (百慕達註冊成立有限公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00289 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 400,000,000 | HKD | | 0.1 | HKD | | 40,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 400,000,000 | HKD | | 0.1 | HKD | | 40,000,000 | 第 2 ...

【财华社讯】WING ON CO(00289.HK)公布，预期截至2025年6月30日止6个月将錄得应拨归股东亏损约 为1.504亿港元，相比2024年同期为亏损2.396亿港元。该亏损减少主要由于截至2025年6月30日止6个月 集团投资组合收益约为2.198亿港元，相比2024年同期收益为1.278亿港元。 本文源自：财华网 ...

Group 1 - The company expects a loss attributable to shareholders of approximately HKD 150 million for the six months ending June 30, 2025, an improvement compared to a loss of approximately HKD 240 million for the same period in 2024 [1] - The reduction in loss is primarily due to an expected investment portfolio income of approximately HKD 219.8 million for the six months ending June 30, 2025, compared to HKD 127.8 million for the same period in 2024 [1][2] - The company anticipates a net loss from the valuation of investment properties of approximately HKD 471 million for the six months ending June 30, 2025, compared to a loss of HKD 516 million for the same period in 2024 [1] Group 2 - Excluding the net loss from investment property valuations and related deferred tax items, the company expects a basic profit attributable to shareholders to increase by approximately 27.1% to about HKD 321 million for the six months ending June 30, 2025, compared to HKD 253 million for the same period in 2024 [1] - The company projects a decrease in investment property income of approximately 17.1% to about HKD 160 million for the six months ending June 30, 2025, down from HKD 193.4 million for the same period in 2024, mainly due to weak demand for office space leading to lower rents and occupancy rates [2] - The department store business is expected to incur a loss of approximately HKD 38.5 million for the six months ending June 30, 2025, compared to a loss of HKD 27 million for the same period in 2024, primarily due to changes in consumer behavior among Hong Kong residents and increased overseas travel and cross-border shopping [2]

Group 1 - The company expects a loss attributable to shareholders of approximately HKD 150 million for the six months ending June 30, 2025, an improvement from a loss of approximately HKD 240 million for the same period in 2024 [1] - The reduction in loss is primarily due to an expected investment portfolio income of approximately HKD 219.8 million for the six months ending June 30, 2025, compared to HKD 127.8 million for the same period in 2024 [1] - The company anticipates a net loss from property valuation of approximately HKD 471 million for the six months ending June 30, 2025, compared to a loss of HKD 516 million for the same period in 2024 [1] Group 2 - The company projects a basic profit attributable to shareholders to increase by approximately 27.1% to about HKD 321 million for the six months ending June 30, 2025, compared to HKD 253 million for the same period in 2024 [1] - The expected investment portfolio income is mainly derived from the revaluation of securities held for trading and gains from the sale of these securities [1] - The company anticipates a decrease in investment property income of approximately 17.1% to about HKD 160 million for the six months ending June 30, 2025, down from HKD 193.4 million for the same period in 2024, due to weak demand for office space [2] Group 3 - The company expects a loss of approximately HKD 38.5 million from its department store business for the six months ending June 30, 2025, compared to a loss of HKD 27 million for the same period in 2024 [2] - The increase in department store losses is attributed to changes in consumer behavior among Hong Kong residents, as well as increased overseas travel and cross-border shopping [2]

Core Viewpoint - WING ON CO (00289.HK) anticipates a loss attributable to shareholders of approximately HKD 150.4 million for the six months ending June 30, 2025, an improvement compared to a loss of HKD 239.6 million for the same period ending June 30, 2024 [1] Financial Performance - The company expects a basic profit attributable to shareholders to increase by approximately 27.1% to about HKD 321.1 million for the six months ending June 30, 2025, compared to a basic profit of HKD 252.6 million for the six months ending June 30, 2024 [1]

(百慕達註冊成立有限公司) (股份代號︰289) 盈利預告 - 虧損減少 截至 2025 年 6 月 30 日止 6 個月 本公告乃本公司根據上市規則第 13.09(2) 條及證券及期貨條例（香港法例第 571 章） 第 XIVA 部項下之內幕消息條文作出。 董事會謹此知會股東及潛在投資者，根據管理層目前掌握截至 2025 年 6 月 30 日止 6 個月未經審核之綜合管理賬目所作的初步審閱，本集團預期截至 2025 年 6 月 30 日止 6 個月將錄得應撥歸股東虧損約為 150.4 百萬港元，相對比截至 2024 年 6 月 30 日止 6 個月則為虧損 239.6 百萬港元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 WING ON COMPANY INTERNATIONAL LIMITED 永安國際有限公司 截至 2025 年 6 月 30 日止 6 個月，本集團於香港及澳洲墨爾本的投資物業收入預期減少約 17.1% 至約 160.3 ...

Core Viewpoint - Lidman plans to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the company and enhance its IVD business segment, particularly in tuberculosis diagnosis and treatment [1][2]. Group 1: Transaction Details - The acquisition involves a cash purchase of shares from shareholders of Xiansheng Xiangrui, with no prior ownership of the target company by Lidman [1]. - The transaction is expected to constitute a major asset restructuring, and Lidman's stock will not be suspended during this process [1][2]. - The funding for the acquisition will come from Lidman's own funds and bank acquisition loans, with the transaction price yet to be determined [2]. Group 2: Company and Industry Insights - Xiansheng Xiangrui operates in the biopharmaceutical manufacturing industry, focusing on in vivo diagnostic reagents and human vaccines, particularly for tuberculosis screening and treatment [1]. - Lidman is one of the earliest companies in China engaged in the research, production, and sales of biochemical diagnostic reagents [2]. - The acquisition is expected to enhance Lidman's competitive edge by adding tuberculosis diagnosis and treatment capabilities, aligning with the interests of the company and its shareholders [2]. Group 3: Market Performance - Lidman's stock has seen a significant increase, with a cumulative rise of over 44% from April 8 to the present, reaching a closing price of 5.87 yuan per share and a total market capitalization of 3.2 billion yuan [3].